Gsk (GSK) Return on Capital Employed (2009 - 2026)
Gsk (GSK) posted quarterly Return on Capital Employed of 11.42% for Q2 2026, up 212.0% year-over-year from 3.66% in Q2 2025, and down 13.31% quarter-over-quarter from 13.18% in Q1 2026.
Gsk (GSK) Return on Capital Employed (2009 - 2026) Analysis & Trends
Gsk's Return on Capital Employed history runs 18 years deep, the most recent figure standing at 11.42% for Q2 2026.
- In Q2 2026, Return on Capital Employed rose 212.0% year-over-year to 11.42%; the TTM figure through Jun 2026 stood at 11.42% (up 212.0% YoY), while the FY2025 annual figure was 9.82%, down 112.0% from the prior year.
- Return on Capital Employed for Q2 2026 stood at 11.42%, down from 13.18% in the prior quarter.
- The five-year high for Return on Capital Employed was 26.36% in Q4 2023, with the low at 7.24% in Q2 2022.
- The 5-year median for Return on Capital Employed is 11.31% (2022), against an average of 12.49%.
- The sharpest annual moves came in 2022 and 2024: Return on Capital Employed jumped 1074 bps in 2022, then slumped 920 bps in 2024.
- Gsk's Return on Capital Employed stood at 22.24% in 2022, then grew by 19 bps to 26.36% in 2023, then tumbled by 35 bps to 17.15% in 2024, then declined by 23 bps to 13.24% in 2025, then dropped by 14 bps to 11.42% in 2026.
- Business Quant data shows GSK's Return on Capital Employed at 11.42% in Q2 2026, 13.18% in Q1 2026, and 13.24% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 17.83% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 17.92% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 9.96% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 16.76% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 16.66% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -5.97% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 11.86% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 11.42% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 79.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.42% |
| Mar 31, 2026 | 13.18% |
| Dec 31, 2025 | 13.24% |
| Sep 30, 2025 | 11.86% |
| Jun 30, 2025 | 9.30% |
| Mar 31, 2025 | 8.91% |
| Dec 31, 2024 | 17.15% |
| Sep 30, 2024 | 9.25% |
| Jun 30, 2024 | 11.74% |
| Mar 31, 2024 | 12.42% |
| Dec 31, 2023 | 26.36% |
| Sep 30, 2023 | 11.18% |
| Jun 30, 2023 | 10.52% |
| Mar 31, 2023 | 9.63% |
| Dec 31, 2022 | 22.24% |
| Sep 30, 2022 | 7.90% |
| Jun 30, 2022 | 7.24% |
| Mar 31, 2022 | 11.20% |
| Dec 31, 2021 | 11.50% |
| Sep 30, 2021 | 8.47% |